HIV-1 persists in a latent reservoir in resting CD4+ T cells despite antiretroviral therapy
(ART). The reservoir decays slowly over the first 7 years of ART (t 1/2= 44 months). However …

HIV-1–infected individuals harbor a latent reservoir of infected CD4+ T cells that is not
eradicated by antiretroviral therapy (ART). This reservoir presents the greatest barrier to an …

Although antiretroviral therapy (ART) is highly effective at suppressing HIV-1 replication, the
virus persists as a latent reservoir in resting CD4+ T cells during therapy. This reservoir …

Combination antiretroviral therapy (ART) for HIV-1 infection reduces plasma virus levels to
below the limit of detection of clinical assays. However, even with prolonged suppression of …

Initiation of antiretroviral therapy during the earliest stages of HIV-1 infection may limit the
seeding of a long-lasting viral reservoir, but long-term effects of early antiretroviral treatment …

The persistence of latently infected, resting CD4+ T cells is considered to be a major
obstacle in preventing the eradication of HIV-1 even in patients who have received effective …

ABSTRACT Central memory (TCM) CD4+ T cells are the principal reservoir of latent HIV-1
infection that persists despite durable, successful antiretroviral therapy (ART). In a study that …

Understanding the origin of HIV variants during viral rebound may provide insight into the
composition of the HIV reservoir and has implications for the design of curative interventions …

The latent reservoir for HIV-1 in resting CD4+ T cells is a major barrier to cure. Several lines
of evidence suggest that the latent reservoir is maintained through cellular proliferation …

Proliferation of CD4+ T cells harboring HIV-1 proviruses is a major contributor to viral
persistence in people on antiretroviral therapy (ART). To determine whether differential rates …